TAK 937
Latest Information Update: 05 Nov 2023
At a glance
- Originator Takeda
- Class Neuroprotectants
- Mechanism of Action Cell differentiation modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Stroke
Most Recent Events
- 21 May 2010 Discontinued - Phase-I for Stroke in Japan (Parenteral)
- 31 Dec 2008 Phase-I clinical trials in Stroke in Japan (Parenteral)